Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Thoracic 2Gynecologic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × surufatinib × 90 days × Clear all
NCT07609121 2026-05-27

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC

Sun Yat-sen University

Phase 2 Not yet recruiting
160 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05494580 2026-03-10

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Sun Yat-sen University

Phase 1/2 Completed
29 enrolled
Gynecologic

Ovarian Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Recruiting
47 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡